Konica Minolta Healthcare expands regenerative medicine products for orthopedics

Alan Condon -   Print  |

Konica Minolta Healthcare Americas partnered with RegenLab USA Feb. 19 to distribute its regenerative medicine portfolio for the orthopedic market in the U.S. and Canada.

Konica's bio-injectable products include preparation devices for platelet-rich plasma and other blood cell therapies, administered using ultrasound guidance.

The single use kits prepare PRP and other cell-based therapies so clinicians can deliver efficiently in their practice.

The regenerative medicine market for sports medicine, orthopedics and pain management is projected to surpass $300 million in North America by 2025, according to a recent report by Grand View Research.

More articles on biologics:
Stryker ranks No. 8 in Fortune's 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers